Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia

Abstract

BackgroundMicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Circulating miRNAs are emerging biomarkers in many diseases and cancers such as type 2 diabetes, pulmonary disease, colorectal cancer, and gastric cancer among others; however, defining a plasma miRNA signature in acute myeloblastic leukemia (AML) that could serve as a biomarker for diagnosis or in the follow-up has not been done yet.MethodsTaqMan miRNA microarray was performed to identify deregulated miRNAs in the plasma of AML patients. Quantitative real-time RT-PCR was used to validate the results. Receiver-operator characteristic (ROC) curve analysis was conducted to evaluate the diagnostic accuracy of the highly and significantly identified deregulated miRNA(s) as potential candidate biomarker(s).ResultsThe plasma expression level of let-7d, miR-150, miR-339, and miR-342 was down-regulated whilst that of let-7b, and miR-523 was up-regulated in the AML group at diagnosis compared to healthy controls. ROC curve analyses revealed an AUC (the areas under the ROC curve) of 0.835 (95% CI: 0.7119– 0.9581; P<0.0001) and 0.8125 (95% CI: 0.6796–0.9454; P=0.0005) for miR-150, and miR-342 respectively. Combined ROC analyses using these 2 miRNAs revealed an elevated AUC of 0.86 (95% CI: 0.7819–0.94; P<0.0001) indicating the additive effect in the diagnostic value of these 2 miRNAs. QRT-PCR results showed that the expression level of these two miRs in complete remission AML patients resembled that of healthy controls.ConclusionsOur findings indicated that plasma miR-150 and miR-342 are novel important promising biomarkers in the diagnosis of AML. These novel and promising markers warrant validation in larger prospective studies.

Circulating microRNA signature of genotype‐by‐age interactions in the long‐lived Ames dwarf mouse

“…That study showed that miR‐342‐5p promotes inflammatory macrophage activation through an Akt1 and miR‐155‐dependent pathway during atherosclerosis (Wei et al ., 2013). In addition, two of the pattern A miRNAs (i.e., miR‐342 and miR‐146) have been associated with inflammation, proliferation, and cancer (Fayyad‐Kazan et al ., 2013). …”

Role of microRNA-150 in solid tumors

“…In addition, miR-150 is significantly downregulated in the majority of acute myeloid leukemia (AML) cases, which is not associated with the DNA copy number changes, methylation or mutations (11). Furthermore, the results of a recent study revealed that the plasma expression of miR-150 was significantly downregulated in AML patients at diagnosis when compared with healthy controls; however, miR-150 plasma expression in complete remission AML patients resembled that of the healthy controls (19). Receiver operating characteristic curve analyses revealed that plasma miR-150 may serve as a valuable biomarker for the differentiation of AML patients from control individuals, with a sensitivity and specificity of 80 and 70%, respectively (19).…”

“…Furthermore, the results of a recent study revealed that the plasma expression of miR-150 was significantly downregulated in AML patients at diagnosis when compared with healthy controls; however, miR-150 plasma expression in complete remission AML patients resembled that of the healthy controls (19). Receiver operating characteristic curve analyses revealed that plasma miR-150 may serve as a valuable biomarker for the differentiation of AML patients from control individuals, with a sensitivity and specificity of 80 and 70%, respectively (19). The expression signature of miR-150 in the plasma indicated that it may serve as a valuable diagnostic and potentially prognostic biomarker for human AML (19).…”

“…Receiver operating characteristic curve analyses revealed that plasma miR-150 may serve as a valuable biomarker for the differentiation of AML patients from control individuals, with a sensitivity and specificity of 80 and 70%, respectively (19). The expression signature of miR-150 in the plasma indicated that it may serve as a valuable diagnostic and potentially prognostic biomarker for human AML (19). Furthermore, in cutaneous T-cell lymphoma, upregulation of miR-150 inhibited tumor invasion and metastasis by targeting the chemokine CCL20 receptor, CCR6 (20).…”

Cell‐to‐cell communication: microRNAs as hormones

“…Our previous studies showed that miR‐155 was significantly overexpressed in monoclonal B‐cell lymphocytosis (MBL) when compared with normal B cells and that miR‐155 overexpression in plasma is a predictor of poor response to therapy (Ferrajoli et al ., 2013). Similar studies have reported that miR‐150 and miR‐342 were significantly downregulated in the plasma of acute myeloid leukemia (AML) patients at diagnosis compared to healthy controls and that these microRNAs are candidate biomarkers and potential predictors of relapse in AML (Fayyad‐Kazan et al ., 2013). In addition, circulating miR‐192 has been found to be significantly downregulated in patients with chronic lymphocytic leukemia (CLL) compared with healthy individuals (Fathullahzadeh et al ., 2016).…”